Prosecution Insights
Last updated: April 19, 2026

Examiner: HOPPE, EMMA RUTH

Tech Center 1600 • Art Units: 1682 1683

This examiner grants 41% of resolved cases

Performance Statistics

40.7%
Allow Rate
-19.3% vs TC avg
72
Total Applications
+46.5%
Interview Lift
1416
Avg Prosecution Days
Based on 27 resolved cases, 2023–2026

Rejection Statute Breakdown

13.5%
§101 Eligibility
11.4%
§102 Novelty
31.4%
§103 Obviousness
28.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18060983 COMPOSITIONS AND METHODS FOR DETECTING GENETIC FEATURES Non-Final OA Singular Genomics Systems, Inc.
19318202 PRIMARY TEMPLATE-DIRECTED AMPLIFICATION AND METHODS THEREOF Non-Final OA BioSkryb Genomics, Inc.
17266193 METHOD FOR SYNTHESIZING SINGLE METAL NANOBRIDGED STRUCTURE AND METHOD FOR MANUFACTURING DNA POINT MUTATION DETECTION SENSOR BY USING SAME Non-Final OA Korea University Research and Business Foundation
17640016 CRISPR EFFECTOR SYSTEM BASED MULTIPLEX CANCER DIAGNOSTICS Final Rejection DANA-FARBER CANCER INSTITUTE, INC.
17264754 Method for Carrying Out Real-Time PCR Final Rejection Robert Bosch GmbH
18251033 METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME Non-Final OA KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
17919152 CRYBETAB2 PREDICTS POOR BREAST CANCER OUTCOME AND SENSITIZES TUMORS TO NUCLEOLIN AND CDK INHIBITION Non-Final OA The Johns Hopkins University
17851545 METHODS OF DETECTING AND TREATING HPV-POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA Final Rejection The University of North Carolina at Chapel Hill
18076279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES Non-Final OA Myriad Genetics, Inc.
17786473 METHOD OF MEASURING CELL-FREE DNA IN SURGICAL DRAIN FLUID TO SELECT ADJUVANT THERAPY Non-Final OA Washington University
19056221 METHODS FOR METHYLATION ANALYSIS OF CELL-FREE DNA Final Rejection Hepta Bio, Inc.
17666215 IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER Non-Final OA ETH ZURICH
17541117 CLOSED NUCLEIC ACID STRUCTURES Final Rejection GEN-PROBE INCORPORATED
18495951 Multiple biomarkers for early diagnosis of multi cancer and uses thereof Non-Final OA NURIBIO CO., LTD
17160450 Biological Sample Collectors and Handling Thereof Final Rejection Global Life Sciences Solutions Operations UK Ltd
18344616 METHODS FOR CLASSIFICATION OF LIVER DISEASE Non-Final OA TENSOR BIOSCIENCES, INC.
18254433 METHODS FOR CLASSIFICATION OF LIVER DISEASE Non-Final OA TENSOR BIOSCIENCES, INC
17993845 MOLECULAR ANALYSES USING LONG CELL-FREE DNA MOLECULES FOR DISEASE CLASSIFICATION Non-Final OA Centre for Novostics Limited
18035850 Compositions and Methods for High Sensitivity Detection of Rare Mutations Non-Final OA CY Molecular Diagnostics, Inc.
17593447 COMPOSITION OF PRIMERS FOR DETECTING HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION Final Rejection ECOLE NATIONALE VETERINAIRE D'ALFORT
18009498 ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE IN ANIMAL SAMPLES Non-Final OA ENDER HOLDING AG
18050795 APPLICATION OF EPIGENETIC CHROMOSOMAL INTERACTIONS IN CANCER DIAGNOSTICS Non-Final OA Oxford BioDynamics, PLC
17886778 EARLY CANCER DIAGNOSIS METHOD AND DIAGNOSTIC KIT USING INTERFERON GAMMA GENE CONCENTRATION MEASUREMENT IN EXOSOMES Final Rejection Yeon Soo KIM
17693129 MULTIPLEXED GENOTYPING ASSAYS WITH A SINGLE PROBE USING FLUORESCENT AMPLITUDE TUNING Final Rejection GT MOLECULAR, LLC
17635219 PROBE-CAPTURE METHOD FOR TCR ALPHA AND BETA CHAIN VDJ-RECOVERY FROM OLIGO-DT REVERSE TRANSCRIBED RNA Final Rejection iRepertoire, Inc.
17542078 NUCLEIC ACID PROBES Final Rejection CYTOTEST INC.
17097408 LUNG CANCER DETERMINATIONS USING MIRNA Final Rejection Ugo Pastorino

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month